Acquisition expands Glooko's digital health capabilities with machine learning BERLIN and PALO ALTO, Calif ., Feb. 1, 2022 /PRNewswire/ -- Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic diseases, announced today the acquisition of xbird, a Berlin-based company specializing in medical artificial intelligence that develops JITAI (just-in-time adaptive interventions) technologies to help patients and their providers predict behavior and manage diabetes. Using the latest artificial intelligence and machine learning, xbird's technology is able to identify health risks for people with diabetes by interpreting medical and behavioral data in a targeted way and providing recommendations. personalized and behavioral encouragement. Sensors via smartphones and wearable devices record a user's movements and analyze the data to create individualized behavioral profiles and personalized encouragement to change patient behavior and lifestyle decisions. The addition of xbird expands Glooko's advanced analytics capabilities and tools, expanding the offerings of the Glooko platform.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!